



AJOONI BIOTECH LIMITED

Regd. Office : D-118, Industrial Area, Phase-VII, Mohali-160055 (Pb.)
Phone : 0172-5020758-69 Website : www.ajoonibiotech.com
E-mail : ajooni.biotech@gmail.com / info@ajoonibiotech.com
CIN: L85190PB2010PLC040162

To,
National Stock Exchange of India Ltd
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400051

Date: 02/08/2021

Dear Sir / Madam,

SYMBOL: AJOONI

Sub.: Approval of Un-audited Financial Results for the quarter ended 30th June, 2021.

Dear Sir,

Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform that the Board of Directors of the Company at their meeting held on 02/08/2021 at the Registered Office of the company have considered and approved the Audited Financial Statements for the quarter ended 30th June, 2021. In this regards, we are enclosing herewith:

1. Un-Audited Financial Results for the quarter ended on 30th June 2021.
2. Limited Review Report from the auditor for the quarter ended on 30th June 2021.

You are requested to kindly take the same on record.

Thanking You,

Yours Truly,

For Ajooni Biotech Limited


Jasjot Singh
Managing Director

DIN: 01937631



AJOONI BIOTECH LIMITED

CIN : L85190PB2010PLC040162

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2021 (In Lakhs)

PARTICULARS	Quarter Ended			Year Ended (Audited)
	30.06.2021	31.03.2021	30.06.2020	
I Income				31.03.2021
Revenue from operations	1,584.62	1,618.80	983.16	30.06.2020
Other income	0.92	0.52	0.51	30.06.2021
Total income from operations	1,585.54	1,619.32	983.67	1,585.54
II Expenses				
Cost of Material Consumed	1,342.82	1,395.36	815.32	815.32
Change In Inventories	(1.49)	(22.74)	(4.03)	(1.49)
Employee benefit expenses	38.10	29.65	32.05	38.10
Finance costs	13.30	15.12	10.44	13.30
Depreciation and amortization expenses	18.93	14.44	15.50	18.93
Payment to NSE				15.50
Other expenses	133.08	182.59	70.61	133.08
Total expenses	1,544.74	1,614.42	939.89	1,544.74
III Profits/(Loss) before exceptional items and tax	40.80	4.90	43.78	40.80
IV Exceptional items				
V Profits/(Loss) before tax	40.80	4.90	43.78	40.80
V1 Tax expenses				
a) Current tax	10.50	1.43	13.60	10.50
b) Deferred tax	1.05	0.95	-	1.05
b) Mar Credit	-	-	-	0
VII Net Profit/(Loss) for the period/year	31.35	4.42	30.18	31.35
VIII Other comprehensive income (net of tax)				
Items that will not be reclassified to profit or loss:	-	(45)	-	-
Total other comprehensive income				
IX Total comprehensive income for the period/year (VII+VIII)	31.35	(40.83)	30.18	31.35
X Paid-up equity share capital (face value of the share shall be indicated)	1,000.55	1,000.55	840.50	1,000.55
XI Other equity (excluding revaluation reserve)	596.69	564.51	748.60	596.69
XII EPS in Rs. (Face Value of Rs.10/- each)*				



7/01

-Basic	0.31	0.04	0.36	0.31	0.36	0.37
-Diluted	0.31	0.04	0.36	0.31	0.36	0.37

Notes:

1. The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 02.08.2021 after being reviewed by the Audit Committee.
2. The company is having single segment in accordance with IND AS 108 "operating segments", and therefore segment reporting is not applicable to the Company.
3. Due to re-grouping of schedules, and as per applicability of IND-AS, there has been a difference in the figures as reported earlier.



For Ajoon Biotech Limited
 Jasjot Singh
 Managing Director
 DIN: 01937631

Date: 02/08/2021

Place : Mohali

AJOONI BIOTECH LIMITED

CIN : L85190PB2010PLC040162

Statement of Assets and Liabilities
For the Year ended on 30th June 2021

in Rs.

PARTICULARS	30TH JUNE 2021	31ST MARCH 2021
I. ASSETS		
(1) Non - Current Assets		
a) Property, Plant and Equipment	51,705,299	51,617,081
b) Financial Assets		
(1) Non-Current Investments	11,316,761	11,482,856
(2) Advances		
c) Deffered Tax Asset	1,570,029	1,465,029
d) Other Non Current Assets	1,055,272	1,407,030
(2) Current Assets		
a) Inventories	53,504,349	53,762,090
b) Financial Assets		
(1) Cash & Cash Equivalent	17,165,795	2,440,976
(2) Short Term Loans and advances	19,912,284	19,882,931
(3) Trade Receivables	137,270,404	137,117,389
c) Other Current Asset	1,087,547	1,087,547
TOTAL Rs.	294,587,741	280,262,930

II EQUITY AND LIABILITIES

(1) Equity		
a) Equity Share Capital	100,055,820	100,055,820
b) Other Equity	59,669,125	56,451,410
(2) Non-Current Liabilities		
a) Financial Liabilities		
(1) Borrowings	22,766,076	18,979,313
(3) Current Liabilities		
a) Financial Liabilities		
(1) Borrowings	54,472,542	48,857,260
(2) Trade Payables	54,848,078	54,003,957
b) Other Current Liabilities	1,726,100	411,890
c) Current tax liabilities (Net)	1,050,000	1,503,280
TOTAL Rs.	294,587,741	280,262,930

Date: 02.08.2021

Place: Mohali

For Ajooni Biotech Limited

Jasjot Singh

Managing Director

DIN: 01937631



Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

(A PEER REVIEWED FIRM)

Limited Review Report on Standalone Financial Results

To Board of Directors of M/s Ajooni Biotech Limited

We have reviewed the Standalone Un-Audited Financial Result of M/s. **Ajooni Biotech Limited** having its Regd. Office at D-118, Industrial Area, Phase VII, Mohali, Punjab-160055 for the Quarter ended 30th June 2021 (“the Statement”) attached herewith ,being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015(as amended), including relevant circulars issued by the Securities and Exchange Board of India ('SEBI') from time to time.

This statement is the responsibility of company’s Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagement to “Review of Interim Financial Information performed by the independent auditor of the entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material mis-statement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone Un-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards (‘ Ind AS’) prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Harjeet Parvesh & Co.
Chartered Accountants

CA Konia Madan
Partner

M.No 547759

Date: 02-08-2021

UDIN: 21547759AAAAAW4351

House No. 1122, Sector 71, Mohali

Mobile :096460-27023, 098120-27023 | E-mail : harjeetca@yahoo.com